Skip To Main Content
Susanna Vogel on Muck Rack

Susanna Vogel

  • Content Marketing Director, Brellium
New York
As seen in: Yahoo Finance, Flipboard, Yahoo, Retail Dive, Genetic Literacy Project, Healthcare Dive, CIO Dive, Morning Brew, CFO, Yahoo Finanzas and
Currently @healthcaredive. Seen in @hr_brew @huffpost @fastcompany @getreworked email me: svogel@industrydive.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Susanna

Contact Susanna, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Kalshi is expanding online betting in drug R&D — unless detractors can stop it Original

|
By Susanna Vogel
| PharmaVOICE Verified
This audio is auto-generated. Please let us know if you have feedback. The online betting company Kalshi is expanding beyond elections and sporting events into a new corner of prediction markets: drug development. The company launched a pilot program this month allowing users to bet on the outcomes of clinical trials, FDA regulatory decisions and drug approvals from companies like Sanofi and Gilead Sciences.
Open in Who Shared View Duplicates (2) Issue with article?

Why the FDA’s top spot could sit empty for months

|
By Susanna Vogel
| MedTech Dive Verified
It’s been over two months since Dr. Marty Makary stepped down from his post as FDA commissioner, and there has yet to be visible progress toward naming his permanent successor. The gap in leadership is sparking concerns among industry watchdogs that pharma could lack clear guidance on federal priorities for weeks or months to come. The FDA has endured long stretches without confirmed leaders before — including a 22-month period under former President George W.
Open in Who Shared Issue with article?

Why the FDA’s top spot could sit empty for months

|
By Susanna Vogel
| PharmaVOICE Verified
This audio is auto-generated. Please let us know if you have feedback. It’s been over two months since Dr. Marty Makary stepped down from his post as FDA commissioner, and there has yet to be visible progress toward naming his permanent successor. The gap in leadership is sparking concerns among industry watchdogs that pharma could lack clear guidance on federal priorities for weeks or months to come.
Open in Who Shared Issue with article?
See all 986 articles